In the evolving field of biochemical research, specific compounds often capture the attention of the scientific community due to their unique me Acceleron shelves drug after disappointing readout chanisms of action. One such compound frequently discussed in laboratory settings is ACE 083 peptide sciences formulations. As researchers explore the frontiers of muscle biology, understanding the precise nature of these molecules is 4 May 2018—The US Food and Drug Administration (FDA) has granted Fast Track designation toACE-083, a locally-acting “Myostatin+” muscle agent, for the treatment of Read more essential for accurate experimental design.
Defining the Compound: Scientific Context
At its core, ACE 083 is a synthetically engineered ligand trap. Unlike systemic agents that circulate throughout the entire body, this molecule is designed for intramuscular injection. It functions as a local acting myostatin inhibitor, which essentially means it works primarily by blocking signals that inhibit muscular growth within the specific area of administration.
While it is frequently colloquially referred to as a "peptide," in technical literature, it is more accurately described as a recombinant fusion pr Acceleron ditches midstage drug after flop otein—a biologic. It belongs to a class of research agents that target a large family of proteins called transforming growth factor beta (TGF-β), which are known to regulate various biological pathways.
Mechanisms and Research Applications
The primary interest in this compound stems from its potential for increased muscle volume. Because ACE 083 is designed to stay local to the muscle you inject it into, it avoids the systemic exposure associated with other pharmacological agents. This localized effect is a significant area of study for those investigating muscle-promoting agents.
Historically, ACE 083 is an experimental therapy developed by Acceleron Pharma that was initially explored for its potential in treating muscle-wasting conditions, such as facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth (CMT) dise 23 Jun 2020—Follistatin-based ligand trapACE-083induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular Read more ase. While developmental paths for these specific clinical indications have shifted, the molecule remains a focal point for researchers studying localized hypertrophy in controlled laboratory models.
Navigating Research Data
When sourcin Study of ACE-083 in Patients With Facioscapulohumeral g ACE 083 for study, researchers often encounter specific identifiers. It is sometimes associated with CAS 81080-10-6, though it is important to distinguish this from other research chemicals, as some databases may list it as a small-molecule compound with antifilarial activity in unrelated parasitology studies.
For those conducting experiments, the A083 research protocol typically emphasizes:
* Targeted Administration: Ensuring the agent is applied to the intended muscle group.
* Storage Requirements: Maintaining the structural integrity of the fusion protein, usually requiring desiccation and storage at -20°C for long-term stability.
* Evaluation Metrics: Researchers often look for quantifiable changes in muscle mass and strength, as ACE-083 shows promising preliminary results in clinical trials regarding its ab ACE-083 shows promising preliminary results in clinical trials ility to induce localized muscle growth.
A Note on Laboratory Best Practices
As with any investigational protein therapeutic, the consistency of results depends heavily on ACE-083 the purity and handling of the compound. ACE-083 is a uniquely engineered peptide designed to selectively enhance muscle and strength, and its efficacy in a research setting is highly dependent on precise application.
Those interested in the ACE 083 peptide should prioritize sourcing from suppliers that provide comp 11 Mar 2020—ACE-083 was an experimental treatment for Charcot-Marie-Tooth (CMT) diseasebeing developed by Acceleron Pharma. It aimed to treat CMT1 (the Read more rehensive documentation, including purity analysis and molecular weight verification (typically around 345.49 g/mol for the small-molecule variant, though fusion protein variants require distinct mass spectrometry validation).
By focusing on the mechanistic properties of ACE 083 and adhering to rigorous laboratory standards, the scientific community continues to gain insights into the complex regulation of muscle tissue. Whether exploring the nuances of myostatin inhibition or the broader implications of TGF-β modulation, this compound remains a significant subject of inquiry for those dedicated to advancing the understanding of musculoskeletal physiology.